Generally occurring within the first two weeks of therapy and often resembling a severe inflammatory reaction, the symptoms of CRS are attributed to a marked increased expression and release of certain cytokines, including IL-6, IL-2R, IL-10, IFN-γ, and TNF-α [227]. Here, IL6 is linked to congenital rubella syndrome.